Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary AngiodemaDavie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S
PMID: 36251573
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participantsMutch P, Bashir M, Jung B, Yi P, Iverson M
PMID: 36200371
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
ASCIA 2022
Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial DesignAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M
EAACI 2022
Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Adult Volunteers and Patients With Hereditary Angioedema Predicts Similar Exposure in Adolescent PatientsSmith MD, Rodgers T, Sharman J, Mutch P, Tachdjian R, Savic S, Farrell C
EAACI 2022
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary AngioedemaAygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD
EAACI 2022
Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedemaDuckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP
KININ 2022
KONFIDENT Phase 3 Trial Design for Sebetralstat (KVD900), a Novel Investigational Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angloedema AttacksLumry WR, Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA, Audhya PK, Smith MD, Yea CM, Riedl MA, Maurer M
EAC 2022
Agreement Between Improvements in Patient Global Impression of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial With Sebetralstat (KVD900) in Patients With Hereditary AngioedemaAudhya P, Smith MD, Williams P, Yea CM, Cohn DM
EAC 2022
Oral Sebetralstat (KVD900) Provides Rapid Inhibition of Plasma Kallikrein and Fast Improvement in Attack Symptoms in Patients With Hereditary AngioedemaSmith MD, Duckworth EJ, Hampton SL, Yea CM, Audhya P, Feener EP
EAC 2022
